Pacer Advisors
DTIL icon

Pacer Advisors’s Precision BioSciences DTIL Stock Holding History

Pacer Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-221
Closed -$69K – 1448
2021
Q1 		$69K Buy
221
+103
+87% +$36.1K ﹤0.01% 1380
2020
Q4 		$29K Buy
+118
New +$28.9K ﹤0.01% 1464

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pacer Advisors's DTIL Position: Q2 2021 in Review

Pacer Advisors sold out of Precision BioSciences (DTIL) in Q2 2021, closing a stake of 221 shares — an estimated $69K sold.

Pacer Advisors first reported a position in DTIL in Q4 2020 and held it in 2 quarters. The position peaked at $69K in Q1 2021. 130 funds tracked by Wall St. Rank hold DTIL as of Q2 2021.

  • Pacer Advisors reported no remaining Precision BioSciences position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 221 Precision BioSciences shares in Q2 2021, an estimated $69K.
  • Pacer Advisors first reported a position in Precision BioSciences in Q4 2020 and held it in 2 quarters.
  • Pacer Advisors's Precision BioSciences position peaked at $69K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.